Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.
Video content above is prompted by the following:
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing
September 4th 2025Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).
Read More